chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm pain; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (arm pain) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm pain). At the time of the report, PAIN IN EXTREMITY (arm pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 12-Sep-2021: Upon internal review on 26-May-2022, significant correction was performed. Added reporter details and updated the report type from Invalid case to Spontaneous. The suspect product coding, event coding and narrative was updated.
Daughter in law states that within a few days after receiving the vaccine the patient's dementia symptoms became worse. States pt started to have worsening effects of forgetfulness, became more aggressive and becoming combative.
Patient works in office building beside the administration building where the health department is located.  She received her 1st COVID vaccine (Moderna) in the health department at approximately 1:10 p.m.  She left the office but returned around 3:50 p.m. complaining of eyes swelling with rash around eyes/eyelids.  She also complained of throat "hurting" from what she felt was from vomiting but had no shortness of breath.  She also felt "itchy".   Had co-worker with her at the time.  PHN asked her to go to Urgent Care since nearest hospital is approximately 45-50 minutes away.  Urgent Care is located 5 mins from the health department.  Co-worker to take her.
This case was reported by a physician and described the occurrence of arm numbness in a 41 year old female subject who was vaccinated with influenza virus vaccine (Fluarix) for prophylaxis. The subject had no adverse events following receipt of prior immunizations with influenza virus vaccine (unknown manufacturer). There were no concurrent medications. On an unspecified date in October 2005, the subject received a dose of Fluarix in the left arm (lot AFLUA138BA). Less than one month following the administration of Fluarix, on an unspecified date in October 2005, the subject experience numbness at the injection site and numbness of the left arm "below the injection site." The subject was seen at a physician's office. At the time of follow-up reporting, 14 February 2006, the events were ongoing. The physician considered the events to probably be related to vaccination with Fluarix.
Started an intense headache a little over 12 hours post vaccine and couldn't sleep. I started to feel nauseas.  I took extra strength Tylenol with some water and a banana and vomitted less than 10 minutes later.  I took some more Tylenol and was able to finally get some sleep. The next two days I felt very tired and a little dizzy so I just rested.  Two weeks later I am having sinus pain (no congestion), headaches, nausea and dizziness.
Prolonged crying for 5 hours - pain to left thigh. Resolved when seen back in office on 4/2/07.
Client was not aware of her pregnancy status and had denied any possibility of her being pregnant at the time of immunization with VZV on 10/15/19. Client discovered her positive pregnancy status on 10/23/19. Merck was informed and Merck adverse event report number is 01392136.
Employee received vaccine on 9/25/17. Employee reported nausea, diarrhea, sweating and pale complexion on 9/26/17. Employee reported localized swelling redness and edema at injection site on 9/27/17.
pt presented lethargic w/apnea spells, paleness & dec HR;episodes responded to stimulation & 02 but cont to have similar episodes heralded by crying spells;pt responded to IV fluids w/2 brief episodes of  02 dropping into 80's while sleep;
Enlarged lymph node same side vaccine was administered; This is a spontaneous report from a contactable consumer. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via intramuscular route of administration in the left arm on 24Apr2021 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via intramuscular route of administration in the arm left on 02Apr2021 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Apr2021, 3 days following vaccination, the patient experienced enlarged lymph node at the same side where vaccine was administered, which resolved within a few days. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event enlarged lymph node same side vaccine was administered was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Initial unsolicited report received from a Physician on 09-MAY-2017. This case involves a female patient (age not reported) who was vaccinated with dose of TETANUS TOXOID (batch number, expiry date, dose and dose in series, route of administration were not reported) in an unknown site on an unspecified date. Patient's medical history and concomitant medications were not reported. On 27-Oct-2014, following the vaccination, the patient had developed allergies to vaccine, red and swollen area twice. Laboratory investigations and corrective treatment were not reported. The outcome of events was not reported. List of documents held by sender: none.
MODERATE HEADACHE (APPROXIMATELY) 1 HOUR AFTER VACCINATION; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's concurrent conditions included: asthma, and allergy to penicillin. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced moderate headache (approximately) 1 hour after vaccination. Treatment medications (dates unspecified) included: paracetamol, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from moderate headache 1 hour after vaccination. This report was non-serious.
On 2/17/00, the pt developed a "full-fledged case of chickenpox," with a fever of 102 and allot of itching. The child's sugar remained stable with varicella, but her insulin pump had to be moved due to many lesions under the occlusive dressing. The pt sought unspecified medical attention. No further information is available. Follow up data states the patient subsequently recovered.
Patient had a headache this morning.  At 11:30am she felt hot, so we took her temperature which was 100.0.  She then walked into another room and had a febrile seizure lasting 30 seconds.  Her face was pale white, her eyes were open and staring off, she moaned initially and then her jaw was stuck open with her tongue making a clicking sound.  She urinated herself and then the seizure ended.
3 weeks later elevated temp (102), aches, chills, dizziness/vertigo, continuing for about 2 weeks.  Same reaction as to first vaccine.  Slowly going away.
This spontaneous report was received from a nurse refers to a 4 months old patient of unknown gender. The patient's relevant medical history, concurrent conditions, concomitant medications, drug reactions or allergies were not reported. On 13-SEP-2017, the patient was vaccinated with improperly stored ROTATEQ (dosing details were not reported) (lot # M044397, expiry date: 20-JUN-2018) orally for prophylaxis. No adverse effects were reported. Temperature excursion was from 0 degree Celsius (C) to 1 degree C (0.8 degree C) for 52 minutes. The previous temperature excursion was reported as from 9 degree C to 25 degree C (10.9 degree C) for 3 hours 17 minutes. The call was because of a data logger. No product quality complaint involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1709USA007014: US-009507513-1709USA007011: US-009507513-1709USA007012: US-009507513-1709USA007013: US-009507513-1709USA000054.
Nausea - Not Diaphoretic  Reports being "lightheaded" No Emesis No Syncope No rash  Reports being cold Reports tightness in throat - EMS activated
ED COURSE & MEDICAL DECISION MAKING     Pertinent Labs & Imaging studies reviewed. (See chart for details) Medications and Allergy list reviewed. Nurses note and old records reviewed EMS Note reviewed: N/A   Likely this is simply a reaction to Covid vaccine, dimer is modestly elevated at 1.7, patient is tachycardic CTA of the chest is performed and negative for PE or other pathology seen ECG is noted to have LVH with strain pattern versus thin body habitus, nonspecific findings, follow-up PCP recommended Discharged with albuterol should help with her sensation in the right chest, Zofran as needed, continue to push fluids, Tylenol or ibuprofen
Chills (on the edge of shivering), Flushed face, general body aches, mild soreness at the vaccination site. Body temperature slightly elevated, but not at the threshold typically identified as a fever (98.9).  Although nothing that would warrant medical attention, this is a greater set of adverse reactions than expected.
Fever; chills; nausea; pain; This is a spontaneous report from a contactable consumer or other non hcp.  A 41-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 via an unspecified route of administration on 01May2021 (Batch/Lot number was not reported) as 2ND DOSE, SINGLE for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 and has not been tested for COVID-19 since the vaccination. It was reported that, on 01May2021, 7 days after second injection the patient experienced fever, chills, nausea, pain.  The outcome of events was not recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
at one day after second injection, her arm got very red and sore, appeared to have welts developing from the inside out. she has been to her doctor and dermatology, she has had more areas develop all over her arms, back, chest, neck, legs
Cough; Shortness of Breath; Chest Tightness; Bone aches; Joint aches; High fever; Loss of appetite; Muscle aches; Headache; This is a spontaneous report from a contactable healthcare professional. A 35-year-old female patient (not pregnant) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL9265), via intramuscular route of administration on 26Jan2021 at 16:30 (at the age of 35-year-old) as single dose in right arm for COVID-19 immunization at workplace clinic. The patient's medical history included immune thrombocytopenia, cold urticaria and diabetes. There was no known allergies. Patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EK9231), via intramuscular route of administration on 05Jan2021 at 15:15 (at the age of 35-year-old) as single dose in right arm for COVID-19 immunisation and experienced sever dizziness, severe headache and nausea, all lasted for 2 days. Patient was not pregnant at the time of vaccination. Concomitant medications included prilosec, zzquil. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Jan2021 at 20:00, the patient experienced severe muscle aches, bone aches, joint aches, high fever, headaches and loss of appetite, all lasted a full 24 hours. On 28Jan2021, day 2 post second shot, the patient experienced new chronic symptoms like cough, chest tightness and shortness of breath, all still present. There was no treatment received for the events. The patient had no COVID prior vaccination and was not tested COVID post vaccination. The clinical outcome of all events was recovered with sequel.  Follow-up attempts are completed. No further information is expected.
This spontaneous report as received from a Certified Medical Assistant refers to an unspecified number of patients of unknown age and gender. The Medical Assistant stated that "a few (Oka/Merck) VARIVAX" were administered to patients since being improperly stored in approximately July 2014" about one month ago". No adverse effects were noted. Additional information has been requested (corresponding containing a request for additional information is scheduled).
Consumer was fully vaccinated with Pfizer vaccine. Contracted COVID Tested positive; Contracted COVID Tested positive; This is a spontaneous report from a contactable consumer or other non hcp.    A patient of unspecified age and gender received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection (Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant was not reported. It was reported, Consumer was fully vaccinated with Pfizer vaccine. Contracted COVID while Tested positive ill with symptoms for one week. On an unspecified date the outcome of the event was unknown.
I had a cough but wasn't too worried, but then I woke up on 07/24/2022 with a sore throat and headache so I tested for COVID-19, and it was positive. I immediately isolated from the rest of my household. The main thing I experienced was extreme and constant fatigue. I also had a significant loss of appetite, cough, and diarrhea. I treated my symptoms with TYLENOL and cough syrup. I tested again on 08/01/2022 and was still positive. I called a doctor at that point who prescribed ZITHROMAX which I did not end up taking. She also prescribed benzonatate for the cough which worked well. Overall, I'm feeling better but am still experiencing fatigue and appetite loss.
When I have a Psoriasis flare up I have plaques all over my arm and legs. They are painful, itchy, and it burns. I had a little flare up around . In February 2022 I noticed it was all over my body including my thumb and back. Last month I noticed that it was not getting better. I thought it was my Otezla medication that wasn't working. I went to see my dermatologist doctor early because of the discomfort. I also start to bleed when it gets really bad. The doctor switched my medication 2 weeks ago to cosentyx injection. The otezla has worked before the vaccine, but after the vaccine it stopped working for me.  My skin is already clearing up very fast after taking the new medication.
Patient received vaccine while sitting.  A couple minutes after standing starts to not feel well.  Sits back down in a chair and faints. Comes to right away.
Severe shaking chills with muscle spasms for 2 hours on 1/22/2021. Fever ranging from 99.5 to 102.0 F for 46 hours in a row, even with Tylenol 1000 mg every 6 hours regularly during that time. Fever never went to normal temp. Time period was starting at 07:30 pm 1/22/21 until 05:30 pm 1/24/21. Additional symptoms during that time period was headache, nausea, loss of appetite, muscle weakness all over, muscle aches all over, pain in hip joints, localized pain at injection site without redness. After 1/24/21 5:30pm dry cough and shortness of breathe developed for following 5 days, causing me to stop with heavy breathing after 1 flight of stairs which normally I can climb without any heavy breathing. Heavy breathing with this same activity level continued then for 3 additional weeks, but I would not have to stop the activity, just breathe heavily. And intermittent dry cough continued also for this time period (total of 3 weeks 5 days).
non-immunocompromised patient received third full dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of INCORRECT DOSE ADMINISTERED (non-immunocompromised patient received third full dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INCORRECT DOSE ADMINISTERED (non-immunocompromised patient received third full dose). At the time of the report, INCORRECT DOSE ADMINISTERED (non-immunocompromised patient received third full dose) had resolved.            No concomitant medication was provided.       No treatment information was provided.
This spontaneous case, initially received from a pharmacist on 29-Oct 2018 concerns a 58-year-old, adult, female patient. The patient had no relevant medical history. The patient's concomitant medications were unknown. On 24-Oct-2018, the patient (under age of 65 year) was administered FLUAD TIV [dose: 0.5 ml, anatomical location: deltoid, route of administration: intramuscular, batch number: 250798, expiry date: 31-May-2019]. No adverse event or adverse reaction was reported. The reporter assessed the event as non-serious. This case (201805052) was linked to the source case: 201805049 due to the same reporter.
Exceeded the 6 month window; body aches; fever; diarrhea; This case was reported by a pharmacist via call center representative and described the occurrence of general body pain in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced general body pain, fever, diarrhea and incomplete course of vaccination. On an unknown date, the outcome of the general body pain, fever and diarrhea were recovered/resolved and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the general body pain, fever and diarrhea to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient developed body aches, fever, and diarrhea that took 10 days to recover from after his 1st dose of Shingrix. The patient exceeded the 6 month window for their 2nd dose of Shingrix, which led to incomplete course of vaccination.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020198042:FU1 deleted
Heavy metallic taste x 1 week Low grade fever x 2 weeks Migraines x 2 weeks  Sore throat x 2 weeks  Bruise at injection site (vaccine administration was painless)
This spontaneous report was received from a healthcare worker regarding to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 06-APR-2016, the patient was vaccinated with an improperly stored dose of VAQTA (lot # L031196, expiry date 05-FEB-2017) dosage regimen and route unknown. Concomitant medications were not reported. The vaccine was subjected to temperature excursion of 25.6 F for a time frame of 132 hours. It was reported there were no previous temperature excursions. Product quality complaint (PQC) was not filed. This report is one of the several reports received from the same reporter. Additional information has been requested.
Sore arm at injection site within an hour or so. 4 days later fever 99.7, chills, body aches, abdominal pain
To ED from MAB infusion clinic with hypoxia; + covid on 10/28/21; also had fever, headache, body aches; Labs: D-dimer: 0.63; CO2: 19; Na: 135; CRP: 9.31; CXR with pulmonary edema, multifocal pneumonia, or other pneumonitis: Meds: Decadrom, Remdesivir, tocilizumab, pulimicort, Brovana nebs/alb nebs; Tessalon perles, singulair, lovenox, zinc, O2 initially on 60% bipap;; 11/15 pt with acute spontaneous pneumothorax, CT inserted; ; 11/22 CT came out; reinserted due to low O2 sats and High O2 need; 11/25 Pneumo resolved; CT removed; O2 @ 4 LPM NC at discharge
had high fever (104) for approx 72hr about 1wk p/vax;sore throat & a rash also occurred during same time period;1st night of sx cried on & off & had trouble sleeping;given APAP & Ibuprofen alternating for fever;dx autism 9/98; Annual follow-up states that in addition to the autism, the pt has heavy metal toxicity and an immune system deficiency.
presenting with symptoms identical to HD.; This is a spontaneous report from a contactable consumer (patient's daughter). A 45-year-old female patient received BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE solution for injection; Batch/Lot number and Expiry date were not reported) via an unspecified route of administration on an unspecified date at a single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient presented with symptoms identical to HD (Huntington's disease) on unspecified date. The event was reported as non-serious. The outcome of the event was unknown.  Information on lot number/batch number has been requested.